Literature DB >> 23111661

Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).

Siddhartha Ganguly, Manik Amin, Clint Divine, Omar S Aljitawi, Sunil Abhyankar, Joseph P McGuirk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23111661     DOI： 10.1007/s00277-012-1607-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  9 in total

Review 1.  Hypomethylating agents after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Guido Kobbe
Journal:  Stem Cell Investig       Date:  2016-11-28

Review 2.  Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Ulrich Germing; Guido Kobbe
Journal:  Int J Hematol       Date:  2017-11-15       Impact factor: 2.490

3.  Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.

Authors:  T Sauer; G Silling; C Groth; F Rosenow; U Krug; D Görlich; G Evers; J Albring; R Besoke; R M Mesters; C Müller-Tidow; T Kessler; T Büchner; W E Berdel; M Stelljes
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

Review 4.  Decitabine: a review of its use in older patients with acute myeloid leukaemia.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

5.  Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Jie-Ke Cui; Yin Xiao; Yong You; Wei Shi; Qing Li; Yi Luo; Lin Jiang; Zhao-Dong Zhong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-10-20

6.  Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment.

Authors:  Ganjun Yu; Yanfeng Wu; Wenying Wang; Jia Xu; Xiaoping Lv; Xuetao Cao; Tao Wan
Journal:  Cell Mol Immunol       Date:  2018-04-05       Impact factor: 11.530

7.  Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors.

Authors:  Carmine Liberatore; Maria Teresa Lupo Stanghellini; Francesca Lorentino; Luca Vago; Matteo Giovanni Carrabba; Raffaella Greco; Sarah Marktel; Andrea Assanelli; Francesca Farina; Consuelo Corti; Massimo Bernardi; Jacopo Peccatori; Katja Sockel; Jan Moritz Middeke; Johannes Schetelig; Anika Bergmann; Christina Rautenberg; Fabio Ciceri; Martin Bornhäuser; Thomas Schroeder; Friedrich Stölzel
Journal:  Ther Adv Hematol       Date:  2022-06-17

8.  [Efficacy of low-dose decitabine in the early relapse of malignant hematological diseases after allogeneic hematopoietic stem cell transplantation].

Authors:  G F Xu; T Chen; H F Liu; S J Lin; L Gao; C Zhang; Y Liu; X Zhang; P Y Kong
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14

9.  Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations.

Authors:  Limin Li; Xiaoqian Zhang; Hongjuan Yu; Mingwen Zhang; Mengyuan Xu; Jie Liu; Yueyue Fu; Hongbin Meng; Chengfang Lyu; Xiaoxia Li; Jin Zhou
Journal:  Onco Targets Ther       Date:  2018-10-12       Impact factor: 4.147
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.